Mols JF - Search Results

1

Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.

Lecrenier N, Beukelaers P, Colindres R, Curran D, De Kesel C, De Saegher JP, Didierlaurent AM, Ledent EY, Mols JF, Mrkvan T, Normand-Bayle M, Oostvogels L, Da Silva FT, Vassilev V, Vinals C, Brecx A. Lecrenier N, et al. Among authors: mols jf. Expert Rev Vaccines. 2018 Jul;17(7):619-634. doi: 10.1080/14760584.2018.1495565. Epub 2018 Jul 20. Expert Rev Vaccines. 2018. PMID: 30028651 Review.

2

Sampling of herpes zoster skin lesion types and the impact on viral DNA detection.

Mols JF, Ledent E, Heineman TC. Mols JF, et al. J Virol Methods. 2013 Mar;188(1-2):145-7. doi: 10.1016/j.jviromet.2012.12.013. Epub 2012 Dec 27. J Virol Methods. 2013. PMID: 23275023

3

Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age.

Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC. Chlibek R, et al. Among authors: mols jf. J Infect Dis. 2013 Dec 15;208(12):1953-61. doi: 10.1093/infdis/jit365. Epub 2013 Jul 31. J Infect Dis. 2013. PMID: 23904292 Clinical Trial.

4

Erratum to: Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults ≥50 Years of Age.

Chlibek R, Bayas JM, Collins H, de la Pinta MLR, Ledent E, Mols JF, Heineman TC. Chlibek R, et al. Among authors: mols jf. J Infect Dis. 2021 Feb 3;223(2):353. doi: 10.1093/infdis/jiaa560. J Infect Dis. 2021. PMID: 33215671 No abstract available.

5

A dynamic transmission model with age-dependent infectiousness and reactivation for cytomegalovirus in the United States: Potential impact of vaccination strategies on congenital infection.

Hogea C, Dieussaert I, Van Effelterre T, Guignard A, Mols J. Hogea C, et al. Hum Vaccin Immunother. 2015;11(7):1788-802. doi: 10.1080/21645515.2015.1016665. Hum Vaccin Immunother. 2015. PMID: 25984886 Free PMC article.

6

Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques.

Lorin C, Segal L, Mols J, Morelle D, Bourguignon P, Rovira O, Mettens P, Silvano J, Dumey N, Le Goff F, Koutsoukos M, Voss G, Tangy F. Lorin C, et al. Naunyn Schmiedebergs Arch Pharmacol. 2012 Dec;385(12):1211-25. doi: 10.1007/s00210-012-0793-4. Epub 2012 Sep 16. Naunyn Schmiedebergs Arch Pharmacol. 2012. PMID: 22983013 Free PMC article.

7

One virus, one lesion--individual components of CIN lesions contain a specific HPV type.

Quint W, Jenkins D, Molijn A, Struijk L, van de Sandt M, Doorbar J, Mols J, Van Hoof C, Hardt K, Struyf F, Colau B. Quint W, et al. J Pathol. 2012 May;227(1):62-71. doi: 10.1002/path.3970. Epub 2012 Feb 17. J Pathol. 2012. PMID: 22127961

8

Fortification of a protein-free cell culture medium with plant peptones improves cultivation and productivity of an interferon-gamma-producing CHO cell line.

Burteau CC, Verhoeye FR, Mols JF, Ballez JS, Agathos SN, Schneider YJ. Burteau CC, et al. Among authors: mols jf. In Vitro Cell Dev Biol Anim. 2003 Jul-Aug;39(7):291-6. doi: 10.1290/1543-706X(2003)039<0291:FOAPCC>2.0.CO;2. In Vitro Cell Dev Biol Anim. 2003. PMID: 14753850

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8 results

Search Page